More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
Aislinn C. Rookwood and Mariah Abney join Ethics Talk to discuss their article, coauthored with Hannah S. Butler-Robbins, Danielle Marie Westmark, and Dr Regina Idoate: “Arts-Based Research Methods to Explore Cancer in Indigenous Communities.”